retatrutide ema approval Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide (LY3437943) | GCGR/GLP-1R Inhibitor
Description
Strengths and Limitations Strengths : The report provides a novel indication for tirzepatide that extends beyond glycemic control into dermatological applications
This shift toward eating for nourishment rather than excess demonstrates a healthy connection with food
For GLP-1 patients, this level of versatility is especially valuable
Annales dEndocrinologie
OG was funded by Brain research UK
Common contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe gastroparesis
